https://doi.org/10.55788/1377cf32
The study reflects the growing attention to lifestyle factors as possible triggers of migraine. Patients are interested in such factors because they can influence these themselves. The use of tobacco, alcohol, and illicit substances may act as triggers of migraine attacks, although hard evidence for this assumption is lacking. Dr Thomas van den Hoek (Leiden University Medical Center, the Netherlands) and colleagues examined the prevalence of substance use by means of a survey in a large migraine cohort and compared it with the general population [1]. The study cohort comprised 5,176 patients from the Leiden Headache Center, and data on substance use in the Dutch general population (n=9,500) were derived from the annual health survey for substances (2016/2017). Of the migraine cohort, 83% were women. The mean age was 45 years; mean number of monthly migraine days was 6.6.
The use of all studied substances was lower in migraine patients than in controls. The odds ratio (OR) for illicit drug use was 0.53 (95% CI 0.45–0.63; P<0.01), for current smoking 0.52 (95% CI 0.47–0.57; P<0.01), for lifetime smoking 0.52 (95% CI 0.48–0.55; P<0.01), and for current alcohol consumption it was 0.44 (95% CI 0.40–0.47; P<0.01). Subanalyses per substance stratified by age groups showed similar trends and differences. Subanalyses of chronic versus episodic migraine patients will be performed in the future.
- Van den Hoek T. Prevalence of substance use in a Dutch migraine population. Abstract A38, EHC 2022, 07–10 December, Vienna, Austria.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Large gaps worldwide in prophylactic treatment of migraine Next Article
Idiopathic intracranial hypertension: key factors influencing visual outcomes »
« Large gaps worldwide in prophylactic treatment of migraine Next Article
Idiopathic intracranial hypertension: key factors influencing visual outcomes »
Table of Contents: EHC 2022
Featured articles
EHF consensus on effective migraine treatment and triptan failure
IHS President: “It is time for operationalisation of ICHD”
Headache Prophylaxis
Intervention
EHF consensus on effective migraine treatment and triptan failure
Sustained long-term effect of occipital nerve stimulation in MICCH
Onabotulinumtoxin A effective in older patients with chronic migraine
What to do when conventional treatment of headache fails in children
Predicting response to medical and surgical treatment of trigeminal neuralgia
Breakthroughs in Understanding Headache
IHS President: “It is time for operationalisation of ICHD”
GWAS identifies 7 loci for cluster headache
Towards precision medicine: salivary CGRP and erenumab response
Persistent headache after stroke: not rare and often overlooked
Additional effects of gepants on top of erenumab
Headache Prevention
Idiopathic intracranial hypertension: key factors influencing visual outcomes
Patients with migraines smoke less, drink less, and use fewer illicit drugs than general population
Related Articles
December 22, 2021
CGRP inhibitor erenumab safe and effective in migraine with aura
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com